ENGLEWOOD, Colo., Aug. 11, 2021 /PRNewswire/ -- Ampio
Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical
company focused on the advancement of immunology-based therapies
for prevalent inflammatory conditions for which there are limited
treatment options, today announced that the company will host
one-on-one investor meetings at the following investor
conferences:
H.C. Wainwright 23rd Annual Global Investment
Conference
Date: September
13-15, 2021
Cantor Fitzgerald Virtual Global Healthcare
Conference
Date: September
27-30, 2021
About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a biopharmaceutical company
primarily focused on the advancement of immunology-based therapies
to treat prevalent inflammatory conditions for which there are
limited treatment options. Ampio's lead drug, Ampion™, is backed by
an extensive patent portfolio with intellectual property protection
extending through 2037 and will be eligible for 12-year FDA market
exclusivity upon approval as a novel biologic under the Biologics
Price Competition and Innovation Act (BPCIA).
Forward Looking Statements
Ampio's statements in this press release that are not historical
fact, and that relate to future plans or events, are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by the use of words such as "could,"
"believe," "expect," "plan," "anticipate," and similar expressions.
These forward-looking statements include statements regarding
Ampio's ability to access equity financing and fund research and
development programs and operations through the fourth quarter of
2022, expectations with respect to Ampion, including its ability to
treat prevalent inflammatory conditions for which there are limited
treatment options (including COVID-19) and its ability to offer the
benefits of steroids without the side effects, the significance of
reported results in early clinical trials, the timing of patient
enrollment for the Phase I Long-COVID trial and the Phase II
COVID-19 trials, the timing and outcome of the Company's
application for Emergency Use Authorization of Ampion in COVID-19
patients with inhalation and intravenous routes of drug delivery,
the term of Ampion's patent protection and the timing and
likelihood of Ampion's approval as a novel biologic under the
BPCIA, including the availability of 12-year FDA market exclusivity
in connection with such approval. These forward-looking statements
are made on the basis of the current beliefs, expectations, and
assumptions of the management of Ampio and are subject to
significant risks and uncertainties that could cause actual results
to differ materially from what may be expressed or implied in these
forward-looking statements. The risks and uncertainties involved
include those detailed from time to time in Ampio's filings with
the Securities and Exchange Commission, including without
limitation, in Ampio's Annual Report on Form 10-K and other
documents filed with the Securities and Exchange Commission. Ampio
undertakes no obligation to revise or update these forward-looking
statements, whether as a result of new information, future events
or otherwise.
Media Contact
Katie Kennedy
katie@gregoryfca.com
610-731-1045
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ampio-pharmaceuticals-to-participate-in-upcoming-virtual-investor-conferences-301352299.html
SOURCE Ampio Pharmaceuticals, Inc.